70 related articles for article (PubMed ID: 12102694)
1. Cost-effectiveness and cost-utility of long-term management strategies for heartburn.
Goeree R; O'Brien BJ; Blackhouse G; Marshall J; Briggs A; Lad R
Value Health; 2002; 5(4):312-28. PubMed ID: 12102694
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
4. What is heartburn worth? A cost-utility analysis of management strategies.
Heudebert GR; Centor RM; Klapow JC; Marks R; Johnson L; Wilcox CM
J Gen Intern Med; 2000 Mar; 15(3):175-82. PubMed ID: 10718898
[TBL] [Abstract][Full Text] [Related]
5. Heartburn: issues in patient management. A roundtable discussion.
Rao G; Davis RH; Peura DA; Wright WL
J Fam Pract; 2005 Jun; 54(6):s1-6. PubMed ID: 16021785
[No Abstract] [Full Text] [Related]
6. Cost-Effectiveness of Histamine
Hammond DA; Kathe N; Shah A; Martin BC
Pharmacotherapy; 2017 Jan; 37(1):43-53. PubMed ID: 27809338
[TBL] [Abstract][Full Text] [Related]
7. Cost-effective Analysis of Proton Pump Inhibitors in Long-term Management of Gastroesophageal Reflux Disease: A Narrative Review.
Jamshed S; Bhagavathula AS; Zeeshan Qadar SM; Alauddin U; Shamim S; Hasan S
Hosp Pharm; 2020 Oct; 55(5):292-305. PubMed ID: 32999499
[No Abstract] [Full Text] [Related]
8. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
Barkun AN; Adam V; Martel M; Bardou M
Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
[TBL] [Abstract][Full Text] [Related]
10. Preventing pressure ulcers in long-term care: a cost-effectiveness analysis.
Pham B; Stern A; Chen W; Sander B; John-Baptiste A; Thein HH; Gomes T; Wodchis WP; Bayoumi A; Machado M; Carcone S; Krahn M
Arch Intern Med; 2011 Nov; 171(20):1839-47. PubMed ID: 21949031
[TBL] [Abstract][Full Text] [Related]
11. Management of heartburn: cost considerations.
Vakil N
Postgrad Med; 2000 May; 107(5 Suppl):35-8; discussion 39. PubMed ID: 19667513
[No Abstract] [Full Text] [Related]
12. Role of the primary care provider in the diagnosis and management of heartburn.
Kushner PR
Curr Med Res Opin; 2010 Apr; 26(4):759-65. PubMed ID: 20095795
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*.
MacLaren R; Campbell J
Crit Care Med; 2014 Apr; 42(4):809-15. PubMed ID: 24365863
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of long-term management strategies for erosive oesophagitis.
Goeree R; O'Brien B; Hunt R; Blackhouse G; Willan A; Watson J
Pharmacoeconomics; 1999 Dec; 16(6):679-97. PubMed ID: 10724795
[TBL] [Abstract][Full Text] [Related]
15. Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection.
Arguedas MR; Heudebert GR; Klapow JC; Centor RM; Eloubeidi MA; Wilcox CM; Spechler SJ;
Am J Gastroenterol; 2004 Jun; 99(6):1023-8. PubMed ID: 15180720
[TBL] [Abstract][Full Text] [Related]
16. Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
Armstrong D; Veldhuyzen van Zanten SJ; Barkun AN; Chiba N; Thomson AB; Smyth S; Sinclair P; Chakraborty B; White RJ;
Aliment Pharmacol Ther; 2005 May; 21(10):1189-202. PubMed ID: 15882239
[TBL] [Abstract][Full Text] [Related]
17. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.
van Marrewijk CJ; Mujakovic S; Fransen GA; Numans ME; de Wit NJ; Muris JW; van Oijen MG; Jansen JB; Grobbee DE; Knottnerus JA; Laheij RJ
Lancet; 2009 Jan; 373(9659):215-25. PubMed ID: 19150702
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
Oba Y
Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
[TBL] [Abstract][Full Text] [Related]
20. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis.
Tran-Duy A; Boonen A; van de Laar MA; Franke AC; Severens JL
Ann Rheum Dis; 2011 Dec; 70(12):2111-8. PubMed ID: 21857027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
